Life Science Investing Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
Life Science Investing Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases 2025 Annual Meeting
Life Science Investing Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference
Life Science Investing Galectin Therapeutics to Present at the American Association for the Study of Liver Disease Liver Meeting 2025
Life Science Investing Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Life Science Investing Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update
Silver Dollar Samples Up to 2,753 g/t AgEq in Underground Sampling Campaign at its La Joya Silver Project
